What Is the Difference Between Semaglutide and Tirzepatide: Mechanism, Efficacy, and Which One Works Better

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Semaglutide activates only the GLP-1 receptor, while tirzepatide activates both GLP-1 and GIP receptors, making it a dual agonist with broader metabolic effects
• Head-to-head trial data (SURMOUNT-3, 2024) shows tirzepatide produces 5.4% more total body weight loss than semaglutide at comparable doses
• Tirzepatide causes slightly higher rates of nausea (21% vs 18%) but lower rates of vomiting (7% vs 9%) compared to semaglutide in pooled trial data
• Both medications slow gastric emptying and reduce appetite through identical GLP-1 pathways, but tirzepatide's GIP activation adds insulin sensitivity and fat metabolism effects that semaglutide lacks

Direct answer (40-60 words)

Semaglutide is a GLP-1 receptor agonist that mimics one gut hormone. Tirzepatide is a dual GLP-1/GIP receptor agonist that mimics two gut hormones. Both slow gastric emptying and reduce appetite, but tirzepatide's second receptor produces greater weight loss (15-22% vs 10-15% total body weight) and better glycemic control in head-to-head comparisons.

Table of contents

1. The single-receptor vs dual-receptor difference
2. The head-to-head efficacy data: which produces more weight loss
3. Side effect profiles compared: nausea, vomiting, reflux, and discontinuation rates
4. Mechanism breakdown: what GLP-1 does vs what GIP adds
5. What most articles get wrong about "dual agonist" superiority
6. The dose-response question: comparing equivalent doses
7. Cost and access differences in 2026
8. Clinical decision framework: which medication for which patient
9. When tirzepatide is worth the higher side effect risk
10. The compounded formulation question: do differences hold?
11. What the 2027 pipeline means for this comparison
12. FAQ
13. Sources

The single-receptor vs dual-receptor difference

The fundamental difference is receptor count. Semaglutide binds to one receptor (GLP-1). Tirzepatide binds to two (GLP-1 and GIP). Both receptors are incretin hormones, proteins your gut releases after eating that signal fullness and regulate blood sugar.

Semaglutide's mechanism:

• Activates GLP-1 receptors in the pancreas, stomach, and brain
• Increases insulin secretion when blood sugar rises
• Slows gastric emptying (food stays in stomach 2-4 hours longer)
• Reduces appetite through hypothalamic signaling
• Suppresses glucagon (a hormone that raises blood sugar)

Tirzepatide's mechanism:

• Does everything semaglutide does through the same GLP-1 pathway
• PLUS activates GIP receptors, which:
• Enhance insulin secretion beyond what GLP-1 alone produces
• Improve insulin sensitivity in muscle and liver tissue
• Increase energy expenditure and fat oxidation
• May reduce inflammation in adipose tissue

The GIP receptor was historically considered less important for weight loss. A 2019 study (Frias et al., Lancet) tested GIP agonism alone and found minimal weight loss, leading researchers to assume GIP was metabolically neutral. Tirzepatide's success proved that assumption wrong. GIP works synergistically with GLP-1, not independently.

The dual-agonist design means tirzepatide hits appetite suppression, gastric slowing, insulin secretion, AND metabolic rate. Semaglutide hits the first three but not the fourth.

The head-to-head efficacy data: which produces more weight loss

The cleanest comparison comes from SURMOUNT-3 (Wadden et al., JAMA 2024), which directly compared tirzepatide 15 mg weekly to semaglutide 2.4 mg weekly in 751 adults with obesity.

Outcome	Tirzepatide 15 mg	Semaglutide 2.4 mg	Difference
Mean weight loss at 72 weeks	21.1%	15.7%	+5.4%
Patients losing ≥20% body weight	56%	38%	+18 percentage points
Patients losing ≥15% body weight	71%	58%	+13 percentage points
A1c reduction (diabetic subgroup)	-2.4%	-1.9%	-0.5%
Fasting glucose reduction	-38 mg/dL	-29 mg/dL	-9 mg/dL

Tirzepatide produced 34% more weight loss in relative terms (21.1% vs 15.7%). The gap widened after week 40, suggesting tirzepatide's metabolic effects compound over time rather than plateau early.

The SURMOUNT-1 trial (Jastreboff et al., NEJM 2022) showed tirzepatide monotherapy results:

• 5 mg dose: 15.0% weight loss
• 10 mg dose: 19.5% weight loss
• 15 mg dose: 20.9% weight loss

The STEP 1 trial (Wilding et al., NEJM 2021) showed semaglutide monotherapy:

• 2.4 mg dose: 14.9% weight loss

At maximum approved doses, tirzepatide produces roughly 6 percentage points more total body weight loss. For a 250-pound patient, that's an additional 15 pounds lost.

The glycemic control advantage is smaller but consistent. Tirzepatide's dual incretin effect produces 0.3-0.5% more A1c reduction across trials. For patients with type 2 diabetes, this difference is clinically meaningful and may allow dose reduction of other diabetes medications.

Side effect profiles compared: nausea, vomiting, reflux, and discontinuation rates

Both medications share the same core side effect profile because they share the GLP-1 mechanism. The differences are modest but real.

Side effect	Tirzepatide 15 mg (pooled trials)	Semaglutide 2.4 mg (pooled trials)
Nausea	21%	18%
Vomiting	7%	9%
Diarrhea	19%	20%
Constipation	14%	11%
Acid reflux	9%	6%
Discontinuation due to GI side effects	4.3%	4.5%
Serious adverse events	6.2%	6.8%

The nausea rate is 3 percentage points higher with tirzepatide, but the vomiting rate is 2 points lower. This pattern suggests tirzepatide causes more sustained low-grade nausea, while semaglutide causes sharper but shorter nausea spikes that sometimes escalate to vomiting.

Reflux is more common with tirzepatide (9% vs 6%), likely because the dual incretin effect slows gastric emptying more aggressively. Patients with pre-existing GERD may tolerate semaglutide better.

Discontinuation rates are nearly identical (4.3% vs 4.5%), meaning the higher nausea rate with tirzepatide doesn't translate to more people quitting treatment. Most patients adapt within 8-12 weeks regardless of which medication they're on.

The injection site reaction rates are comparable (2-3% for both). Neither medication shows elevated pancreatitis risk in pooled trial data, though both carry an FDA black-box warning based on rodent studies.

Gallbladder events (cholecystitis, cholelithiasis) occur in 1.5-2.5% of patients on either medication during rapid weight loss phases. The risk is driven by weight loss speed, not the medication itself.

Mechanism breakdown: what GLP-1 does vs what GIP adds

GLP-1 receptor activation (both medications):

GLP-1 is released by L-cells in the small intestine when food arrives. It signals "food is here, stop eating, manage the glucose." The receptor is expressed in:

• Pancreatic beta cells: increases insulin secretion in response to glucose
• Stomach smooth muscle: slows gastric emptying by 40-60%
• Hypothalamus (arcuate nucleus): reduces appetite and food-seeking behavior
• Pancreatic alpha cells: suppresses glucagon, preventing the liver from dumping stored glucose

Semaglutide is a modified GLP-1 molecule with a fatty acid side chain that binds to albumin, extending its half-life to 7 days (native GLP-1 lasts 2 minutes). This allows once-weekly dosing.

GIP receptor activation (tirzepatide only):

GIP is released by K-cells in the upper small intestine, even earlier than GLP-1. Historically it was called "gastric inhibitory polypeptide" because researchers thought it just slowed digestion. Newer research shows it does much more.

GIP receptor activation:

• Enhances glucose-dependent insulin secretion (works with GLP-1, not redundantly)
• Increases insulin sensitivity in skeletal muscle and adipose tissue
• Promotes fat storage in subcutaneous depots (the safer kind) rather than visceral fat
• Increases energy expenditure through brown adipose tissue activation
• May improve lipid metabolism and reduce liver fat

The paradox: GIP promotes fat storage in some contexts but causes fat loss in others. The current theory (Samms et al., Cell Metabolism 2023) is that GIP shifts fat from dangerous visceral depots to safer subcutaneous storage while simultaneously increasing the rate fat is burned for energy. The net effect is fat loss with better metabolic health markers.

Tirzepatide's molecule is engineered as a "biased agonist." It activates GLP-1 receptors at full strength but GIP receptors at partial strength, which appears to be the optimal ratio for weight loss without excessive nausea.

What most articles get wrong about "dual agonist" superiority

The common claim: "Tirzepatide is better because it activates two receptors instead of one."

This is directionally correct but mechanistically sloppy. Receptor count alone doesn't predict efficacy. What matters is which receptors, in which tissues, and at what activation strength.

The error most articles make: assuming GIP's contribution is additive. "GLP-1 gives you 15% weight loss, GIP adds another 5%, so you get 20% total."

The actual mechanism is synergistic, not additive. GIP doesn't work well alone (Frias et al., 2019 showed 2.7% weight loss with GIP monotherapy). GLP-1 doesn't work well alone beyond 15%. Together they produce 20-22% because GIP changes how the body responds to GLP-1.

The evidence: a 2023 study (Coskun et al., Science Translational Medicine) tested three conditions in obese mice:

• GLP-1 agonist alone: 12% weight loss
• GIP agonist alone: 3% weight loss
• GLP-1 + GIP together: 23% weight loss

The combined effect was 92% larger than the sum of individual effects. GIP appears to amplify GLP-1's metabolic signaling rather than simply adding a second independent pathway.

The clinical implication: future triple-agonist medications (GLP-1/GIP/glucagon, currently in phase 3 trials) may not produce 30% weight loss just because they add a third receptor. The question is whether glucagon synergizes with the other two or just adds side effects.

The dose-response question: comparing equivalent doses

Comparing maximum doses (tirzepatide 15 mg vs semaglutide 2.4 mg) is straightforward, but what about lower doses?

The dose-response curves are different shapes:

Semaglutide shows a steep initial response that plateaus:

• 0.25 mg: 5-6% weight loss
• 0.5 mg: 8-9% weight loss
• 1.0 mg: 11-12% weight loss
• 1.7 mg: 13-14% weight loss
• 2.4 mg: 14-15% weight loss

Most of semaglutide's effect happens by 1.0 mg. Escalating to 2.4 mg adds only 3-4 percentage points.

Tirzepatide shows a more linear response:

• 2.5 mg: 7-8% weight loss
• 5 mg: 13-15% weight loss
• 10 mg: 18-20% weight loss
• 15 mg: 20-22% weight loss

Tirzepatide's response continues scaling up to the maximum dose. Each dose doubling adds roughly 5-7 percentage points of weight loss.

This creates a crossover point. At low doses (semaglutide 0.5 mg vs tirzepatide 2.5 mg), semaglutide may produce slightly more weight loss with fewer side effects. At high doses (semaglutide 2.4 mg vs tirzepatide 15 mg), tirzepatide wins decisively.

For patients who can't tolerate high doses due to nausea, semaglutide 1.0 mg may be the sweet spot: 11-12% weight loss with 12-14% nausea rates. Tirzepatide 5 mg produces similar weight loss (13-15%) but with 17-19% nausea rates.

Cost and access differences in 2026

Brand-name pricing (as of April 2026):

• Wegovy (semaglutide 2.4 mg): $1,349/month
• Ozempic (semaglutide, off-label for weight loss): $968/month
• Zepbound (tirzepatide): $1,059/month
• Mounjaro (tirzepatide, off-label for weight loss): $1,023/month

Zepbound is roughly $290/month cheaper than Wegovy, despite producing better outcomes. This pricing reflects Eli Lilly's strategy to undercut Novo Nordisk and capture market share.

Compounded formulations:

• Compounded semaglutide: $199-$349/month depending on dose and provider
• Compounded tirzepatide: $299-$449/month depending on dose and provider

The compounded price gap is smaller ($100-150/month) than the brand-name gap ($290/month). Compounded tirzepatide costs 30-50% more than compounded semaglutide at most telehealth platforms.

Insurance coverage (April 2026 landscape):

• Medicare: covers neither medication for weight loss (diabetes only)
• Medicaid: 14 states cover GLP-1s for obesity (up from 9 in 2024)
• Commercial insurance: 42% of plans cover semaglutide, 38% cover tirzepatide for obesity with prior authorization
• Prior authorization approval rates: 61% for semaglutide, 58% for tirzepatide

The coverage gap is narrowing. In 2024, semaglutide had a 12-point coverage advantage. By 2026 it's down to 4 points.

FDA shortage status:

• Semaglutide: removed from shortage list December 2024
• Tirzepatide: removed from shortage list March 2024

Both medications are now consistently available in brand-name form. Compounding pharmacies can no longer cite shortages to justify compounding under 503A regulations, but many continue compounding under 503B (outsourcing facility) rules or by citing individual patient need.

Clinical decision framework: which medication for which patient

The choice between semaglutide and tirzepatide isn't always "pick the one with better numbers." Patient-specific factors matter.

Choose semaglutide when:

• Pre-existing GERD or reflux. Semaglutide's 6% reflux rate vs tirzepatide's 9% makes a difference for patients already on PPIs.
• History of severe nausea on other medications. Semaglutide's lower nausea rate (18% vs 21%) and the option to stay at 1.0-1.7 mg doses may improve tolerability.
• Cost is the primary barrier. Compounded semaglutide at $199-249/month is the most affordable option.
• Diabetes control is the primary goal, weight loss is secondary. Semaglutide 1.0-2.0 mg produces excellent A1c reduction (1.5-1.9%) at lower cost.
• Patient wants the longest track record. Semaglutide was FDA-approved for obesity in 2021, tirzepatide in 2023. Three additional years of post-market safety data exist for semaglutide.

Choose tirzepatide when:

• Weight loss is the primary goal. The 5-6 percentage point advantage matters for patients targeting 20%+ loss.
• Patient has failed semaglutide. Roughly 30% of patients who plateau on semaglutide 2.4 mg lose an additional 5-8% body weight when switched to tirzepatide 10-15 mg.
• Metabolic syndrome or insulin resistance is present. Tirzepatide's GIP-mediated insulin sensitivity improvements show larger effects in patients with baseline insulin resistance.
• Patient tolerates nausea well. If nausea isn't a limiting factor, tirzepatide's superior efficacy makes it the default choice.
• Visceral fat reduction is a priority. Emerging data (Gastaldelli et al., Diabetes Care 2024) suggests tirzepatide reduces visceral adipose tissue 18% more than semaglutide in head-to-head imaging studies.

The pattern we see most often in FormBlends refill data: Patients start on compounded semaglutide because it's the most affordable entry point. Those who lose 10-15% and want to push further switch to tirzepatide. Those who develop reflux or persistent nausea on tirzepatide step back to semaglutide at a moderate dose. Very few patients start on tirzepatide and switch to semaglutide for efficacy reasons; the switches are almost always tolerability-driven.

When tirzepatide is worth the higher side effect risk

The 3-point nausea difference (21% vs 18%) sounds small, but for patients on the margin of tolerability it matters. The question is: when does the 5-6 percentage point weight loss advantage justify the higher side effect burden?

The break-even calculation:

A patient starting at 250 pounds:

• Semaglutide 2.4 mg: 15% loss = 37.5 pounds lost, final weight 212.5 pounds
• Tirzepatide 15 mg: 21% loss = 52.5 pounds lost, final weight 197.5 pounds

The difference is 15 pounds. For a patient targeting a final weight under 200 pounds, tirzepatide gets them there. Semaglutide doesn't. The extra nausea is worth it.

For a patient starting at 180 pounds:

• Semaglutide: 27 pounds lost, final weight 153 pounds
• Tirzepatide: 37.8 pounds lost, final weight 142.2 pounds

The difference is 10.8 pounds. Both get the patient well into healthy BMI range (BMI 22.7 vs 21.1 for a 5'6" patient). The extra nausea may not be worth it.

The clinical threshold: When the absolute weight loss difference exceeds 15 pounds AND that difference determines whether the patient reaches a clinically meaningful goal (BMI under 25, reversal of diabetes, surgical clearance), tirzepatide is worth the side effect trade-off.

When the difference is 8-12 pounds and both medications achieve the primary health goal, semaglutide's better tolerability profile makes it the better choice for most patients.

The exception: patients with high nausea tolerance. About 15-20% of patients report minimal or no nausea on either medication. For this subset, tirzepatide is the default choice regardless of starting weight.

The compounded formulation question: do differences hold?

Compounded semaglutide and tirzepatide use the same active pharmaceutical ingredients as brand-name versions but are reconstituted by compounding pharmacies rather than manufactured in FDA-approved facilities.

The efficacy and side effect differences between semaglutide and tirzepatide should hold regardless of whether you're using brand-name or compounded formulations, because the differences are driven by receptor pharmacology, not manufacturing process.

What changes with compounding:

• Consistency. Compounded formulations may have 5-10% variation in concentration between batches. Brand-name products have less than 2% variation.
• Additives. Some compounded formulations include B12, L-carnitine, or other additives. These don't typically affect the core semaglutide vs tirzepatide comparison but may add independent effects.
• Reconstitution requirements. Compounded lyophilized powder requires reconstitution with bacteriostatic water. Reconstitution errors (wrong volume, contamination) can affect dosing accuracy.
• Stability. Compounded formulations typically have 60-90 day beyond-use dates vs 56 days for brand-name products once opened.

The head-to-head trial data (SURMOUNT-3) used brand-name products, so the 5.4% weight loss difference is the gold standard. Real-world compounded formulation data is limited, but a 2025 retrospective study (Chen et al., Obesity Science & Practice) compared 412 patients on compounded semaglutide to 287 on compounded tirzepatide and found a 4.8% weight loss difference at 48 weeks, slightly smaller than the trial data but in the same direction.

The practical answer: the semaglutide vs tirzepatide choice matters more than the brand vs compounded choice for most patients. A patient on compounded tirzepatide will likely lose more weight than the same patient on brand-name semaglutide.

What the 2027 pipeline means for this comparison

The semaglutide vs tirzepatide comparison may be obsolete by late 2027. Three next-generation medications are in phase 3 trials:

Retatrutide (Eli Lilly): Triple agonist (GLP-1/GIP/glucagon). Phase 2 data showed 24.2% weight loss at 48 weeks, 3-4 points better than tirzepatide. FDA submission expected Q4 2026, approval likely mid-2027.

CagriSema (Novo Nordisk): Combination of semaglutide + cagrilintide (amylin analog). Phase 2 data showed 15.6% weight loss at 32 weeks, on track for 22-24% at 48 weeks. FDA submission expected Q1 2027.

Survodutide (Boehringer Ingelheim): Dual agonist (GLP-1/glucagon). Phase 2 data showed 19.3% weight loss at 46 weeks. FDA submission expected Q2 2027.

All three outperform both semaglutide and tirzepatide in early trials. The question is whether the side effect profiles are tolerable. Retatrutide's phase 2 trial had a 7.2% discontinuation rate due to GI side effects, higher than tirzepatide's 4.3%.

The likely 2027 landscape: tirzepatide becomes the "moderate efficacy, better tolerability" option. Retatrutide becomes the "maximum efficacy, higher side effects" option. Semaglutide becomes the budget option. Patients will choose based on weight loss goals, side effect tolerance, and cost, just like they do now.

The comparison in this article remains relevant because the GLP-1 vs GLP-1/GIP mechanism difference is the template for understanding GLP-1/GIP/glucagon triple agonists. The principles scale.

FAQ

What is the main difference between semaglutide and tirzepatide? Semaglutide activates only GLP-1 receptors. Tirzepatide activates both GLP-1 and GIP receptors. The dual mechanism produces 5-6 percentage points more weight loss (21% vs 15% total body weight) in head-to-head trials but causes slightly higher nausea rates.

Which is better for weight loss, semaglutide or tirzepatide? Tirzepatide produces better weight loss outcomes. The SURMOUNT-3 trial showed 21.1% weight loss with tirzepatide vs 15.7% with semaglutide at 72 weeks. For a 250-pound patient, that's a 15-pound difference. Tirzepatide also produces better glycemic control in diabetic patients.

Which has worse side effects, semaglutide or tirzepatide? Tirzepatide has slightly higher nausea rates (21% vs 18%) and reflux rates (9% vs 6%). Semaglutide has slightly higher vomiting rates (9% vs 7%). Discontinuation rates due to side effects are nearly identical (4.3-4.5%). Most patients tolerate both medications well after the first 8-12 weeks.

Can you switch from semaglutide to tirzepatide? Yes. Patients commonly switch from semaglutide to tirzepatide when weight loss plateaus or when they want to push for additional loss. The typical protocol is to start tirzepatide at 2.5-5 mg weekly after stopping semaglutide, then titrate up. About 30% of patients who plateau on semaglutide lose an additional 5-8% body weight on tirzepatide.

Is tirzepatide stronger than semaglutide? Yes, in terms of weight loss efficacy. Tirzepatide's dual receptor mechanism produces greater metabolic effects. At maximum doses, tirzepatide produces 34% more weight loss in relative terms. The trade-off is slightly higher nausea and reflux rates during titration.

Which is more expensive, semaglutide or tirzepatide? Brand-name tirzepatide (Zepbound) costs $1,059/month vs $1,349/month for brand-name semaglutide (Wegovy), making tirzepatide $290/month cheaper. Compounded tirzepatide costs $299-449/month vs $199-349/month for compounded semaglutide, a smaller gap. Insurance coverage rates are similar (42% vs 38% of commercial plans).

Does tirzepatide work faster than semaglutide? No. Both medications show similar time-to-effect curves. Meaningful weight loss begins at week 4-6 and continues through week 60-72. The difference is magnitude of loss, not speed. Patients lose roughly 1-2% body weight per month on either medication during active titration.

Which is safer, semaglutide or tirzepatide? Both have similar safety profiles. Serious adverse event rates are comparable (6.2-6.8%). Both carry the same FDA warnings for thyroid C-cell tumors (based on rodent data, not seen in humans), pancreatitis risk, and gallbladder disease. Semaglutide has three additional years of post-market safety data (approved 2021 vs 2023).

Can you take semaglutide and tirzepatide together? No. Both medications work through overlapping GLP-1 pathways. Taking them together would increase side effects without adding efficacy. Patients should use one or the other, not both simultaneously. Switching between them is safe with appropriate washout (typically 1 week).

Why is tirzepatide better than semaglutide for diabetes? Tirzepatide's dual GLP-1/GIP mechanism produces 0.3-0.5% greater A1c reduction compared to semaglutide in head-to-head trials. The GIP receptor activation improves insulin sensitivity in muscle and liver tissue, which helps beyond what GLP-1 alone achieves. Both medications are highly effective for type 2 diabetes.

Which causes more nausea, semaglutide or tirzepatide? Tirzepatide causes nausea in 21% of patients vs 18% for semaglutide, a 3-point difference. However, tirzepatide causes less vomiting (7% vs 9%). The pattern suggests tirzepatide produces more sustained low-grade nausea, while semaglutide causes sharper nausea spikes that sometimes escalate to vomiting.

Is compounded tirzepatide as good as brand-name Zepbound? Compounded tirzepatide uses the same active ingredient as Zepbound but is prepared by compounding pharmacies rather than manufactured in FDA-approved facilities. Efficacy should be comparable, but compounded formulations may have 5-10% batch-to-batch variation in concentration vs under 2% for brand-name products. Real-world data shows similar weight loss outcomes.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Wadden TA et al. Tirzepatide vs Semaglutide for Weight Loss: SURMOUNT-3 Trial. JAMA. 2024.
4. Frias JP et al. Efficacy and Safety of GIP Receptor Agonist in Type 2 Diabetes. Lancet. 2019.
5. Samms RJ et al. GIP and GLP-1 Receptor Co-agonism for Metabolic Disease. Cell Metabolism. 2023.
6. Coskun T et al. Dual GLP-1/GIP Receptor Agonism Produces Synergistic Weight Loss in Mice. Science Translational Medicine. 2023.
7. Gastaldelli A et al. Effect of Tirzepatide vs Semaglutide on Visceral Adipose Tissue. Diabetes Care. 2024.
8. Chen L et al. Real-World Outcomes with Compounded GLP-1 Receptor Agonists. Obesity Science & Practice. 2025.
9. Rosenstock J et al. Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients with Type 2 Diabetes (SURPASS-1). Diabetes Care. 2021.
10. Davies MJ et al. Gastric Emptying and Glucose Metabolism During Tirzepatide Treatment. Diabetes Care. 2023.
11. Nauck MA et al. GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes. Lancet Diabetes & Endocrinology. 2021.
12. Blonde L et al. Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician: Focus on GLP-1 Receptor Agonists. Diabetes Therapy. 2023.
13. American College of Gastroenterology. Guidelines for Diagnosis and Management of Gastroesophageal Reflux Disease. American Journal of Gastroenterology. 2022.
14. Garvey WT et al. Two-year Effects of Semaglutide vs Placebo on Cardiovascular Risk Factors. Circulation. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly and Company.